Login to Your Account

Broad-scope epitopes: Influenza phase II data push a step Biondvax

By Randy Osborne
Staff Writer

Tuesday, June 30, 2015

With a progressive strategy that's "building an ecosystem," Biondvax Pharmaceuticals Ltd. offered upbeat preliminary results from the BVX-006 phase II trial gauging the worth of M-001 in the firm's quest for a universal influenza vaccine.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription